Hi! Our team got
Silver Medal
in iGEM Grand Jamboree 2023!
Click or Scroll Down to start
Our story begins in...
Our story begins in...
In Hong Kong
Lung cancer is
The No. 1 commonly diagnosed cancer
Accounting for 26.7% of all cancer-related mortalities
Annually, air pollution results in the loss of countless lives worldwide.
Particles found in vehicle and smoke from fossil fuels are associated with NSCLC risk, accounting for over 250,000 of these fatalities.
Cigarette smoking is the leading cause of lung cancer esp. NSCLC, accounting for nearly 90% of the risk in men and nearly 80% in women.

Lung cancer is a malignant tumor that originated in the lungs and may spread to lymph nodes or other surrounding organs in the body. It can be categorized into two main types:

Non-Small Cell Lung Carcinoma (NSCLC)

Small Cell Lung Carcinoma (SCLC)

Lung cancer

The 2nd common cancer worldwide

Leading cause of cancer-related mortalities worldwide

Commonly diagnosed at advanced stages with limited treatment options


The current first-line treatment used to treat patients with advanced-stage NSCLC.

Third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).

Specified for NSCLC patients with EGFR T790M mutation.


Osimertinib Resistance Inevitably Develops Among NSCLC Patients

Osimertinib resistance

Develops in EGFR T790M mutation-positive NSCLC patients

Osimertinib is no longer able to halt the growth of NSCLC tumor

Nonetheless, the story doesn’t conclude here!

We, PolYneer, are committed to developing a novel bispecific antibody using a synthetic biology approach to address the unmet clinical need for new agent to overcome Osimertinib resistance in NSCLC patients.


Primary binding site:

Targeting c-MET

Secondary binding site:

Their hands are made by cyclic peptides targeting EGFR

Traditional bispecific antibody production (e.g. amivantamab) relies on the co-culture of two different cell types expressing half of the light-heavy chain of the antibody, and the subsequent dimerization of the half antibody secreted by the two cell types.

Due to the complicated production process:

The therapy cost of traditional bispecific antibody is very high

Ranging from USD 30,000 to USD 170,000 per treatment, which is barely affordable to most patients

Advantages of Polyneerab

Flexible design

Lower production cost

Rapid production

More stable structure and intact Fab conformation as no protein refolding is involved

With Polyneerab in combination with Osimertinib, we believe that we can give renewed hope to NSCLC patients!!

Our Promotion Video

To learn more details about our project, you can visit our specific pages

Our Sponsors